RMTI
ELTX

Nissenson Allen

Known title: DirectorCIK: 0001441889

Nissenson Allen's purchase track record

Nissenson Allen has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
5/19/2022ELTX$11K-17.7%-30.5%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 8, 2026

Rockwell Medical Ranked 16th on Fortune Best Workplaces List. Rockwell Medical was named the 16th best workplace in manufacturing and production on Fortune's 2026 list. This recognition highlights the company's internal culture and employee satisfaction. While not a direct financial metric, such rankings can support long-term talent retention and brand reputation.

this person other insiders at RMTI

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 29, 2026

ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target. Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.

this person other insiders at ELTX

Transaction History

RMTI▲ Buy$0
RMTI▲ Buy$0
RMTI▲ Buy$0
RMTI▲ Buy$0
RMTI▲ Buy$0
ELTX▲ Buy$2K
ELTX▲ Buy$9K

We use analytics to understand how market-wall is used. No personal data is sold.